Eosinophilic Esophagitis Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight

Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, Eosinophilic Esophagitis pipeline constitutes 25+ key companies continuously working towards developing 30+ Eosinophilic Esophagitis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Eosinophilic Esophagitis Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Eosinophilic Esophagitis Market.

The Eosinophilic Esophagitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Eosinophilic Esophagitis Pipeline Report: https://www.delveinsight.com/sample-request/eosinophilic-esophagitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Eosinophilic Esophagitis treatment therapies with a considerable amount of success over the years. Eosinophilic Esophagitis Key players such as - Serpin Pharma, Landos Biopharma, Aqilion, Calypso Biotech, Pfizer, EsoCap, Revolo Biotherapeutics, Ellodi Pharmaceuticals, AstraZeneca, and others, are developing therapies for the Eosinophilic Esophagitis treatment
• Eosinophilic Esophagitis Emerging therapies such as - SP 16, Omilancor, AQ280, CALY-002, Etrasimod, Mometasone, IRL201104, APT-1011, Benralizumab, and others are expected to have a significant impact on the Eosinophilic Esophagitis market in the coming years.
• In February 2025, In February 2025, Bristol Myers Squibb removed cendakimab from its development pipeline as part of ongoing cost-reduction efforts. Although the therapy met its Phase 3 endpoints for eosinophilic esophagitis (EoE), the company chose not to move forward with commercialization, effectively sidelining a potential market competitor to DUPIXENT and Takeda's EOHLIA.
• In December 2024, Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company focused on developing novel biologics with potential for enhanced efficacy and dosing in major inflammatory and immunology (I&I) markets, including atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), eosinophilic esophagitis (EoE), and other I&I conditions, has announced the initiation of dosing healthy volunteers in its clinical trial of APG333. APG333 is a novel subcutaneous (SQ) monoclonal antibody with an extended half-life, targeting thymic stromal lymphopoietin (TSLP), and is being evaluated initially as a treatment for asthma, COPD, and other I&I conditions.
• In December 2024, Sanofi is conducting a parallel Phase 4 study, which includes a 24-week (0.5 years) randomized, double-blind, placebo-controlled treatment phase, followed by an open-label phase of 104 weeks (2 years), for a total duration of 128 weeks (2.5 years). The study aims to assess the impact of dupilumab treatment on esophageal function and remodeling in adults with eosinophilic esophagitis.
• In February 2024, The US Food and Drug Administration (FDA) has approved budesonide oral suspension (Eohilia, Takeda), marking it as the first oral treatment for eosinophilic esophagitis (EoE). This corticosteroid is indicated for 12 weeks of treatment for EoE in adults and children aged 11 and older.

Eosinophilic Esophagitis Overview
Eosinophilic Esophagitis (EoE) is a chronic immune system-mediated condition where a type of white blood cell called eosinophils build up in the esophagus, causing inflammation and damage. This condition often leads to symptoms such as difficulty swallowing, food impaction, chest pain, and reflux. It is commonly triggered by food allergies or environmental allergens and may be treated with medications like corticosteroids, dietary changes, or other therapies to reduce inflammation and manage symptoms.

Get a Free Sample PDF Report to know more about Eosinophilic Esophagitis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/eosinophilic-esophagitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Eosinophilic Esophagitis Drugs Under Different Phases of Clinical Development Include:
• SP 16: Serpin Pharma
• Omilancor: Landos Biopharma
• AQ280: Aqilion
• CALY-002: Calypso Biotech
• Etrasimod: Pfizer
• Mometasone: EsoCap
• IRL201104: Revolo Biotherapeutics
• APT-1011: Ellodi Pharmaceuticals
• Benralizumab: AstraZeneca

Route of Administration
Eosinophilic Esophagitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Intravenous

Molecule Type
Products have been categorized under various Molecule types, such as
• Peptide
• Protein
• Propylene glycols
• Cell Therapy

Eosinophilic Esophagitis Pipeline Therapeutics Assessment
• Eosinophilic Esophagitis Assessment by Product Type
• Eosinophilic Esophagitis By Stage and Product Type
• Eosinophilic Esophagitis Assessment by Route of Administration
• Eosinophilic Esophagitis By Stage and Route of Administration
• Eosinophilic Esophagitis Assessment by Molecule Type
• Eosinophilic Esophagitis by Stage and Molecule Type

DelveInsight's Eosinophilic Esophagitis Report covers around 30+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Eosinophilic Esophagitis product details are provided in the report. Download the Eosinophilic Esophagitis pipeline report to learn more about the emerging Eosinophilic Esophagitis therapies
https://www.delveinsight.com/sample-request/eosinophilic-esophagitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Eosinophilic Esophagitis Therapeutics Market include:
Key companies developing therapies for Eosinophilic Esophagitis are - Bristol Myers Squibb, Ellodi Pharmaceuticals, AstraZeneca, Kyowa Hakko Kirin, Allakos, Pfizer, Revolo Biotherapeutics, EsoCap AG, NexEos Diagnostics, Inc., Celgene, and others.

Eosinophilic Esophagitis Pipeline Analysis:
The Eosinophilic Esophagitis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Eosinophilic Esophagitis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Eosinophilic Esophagitis Treatment.
• Eosinophilic Esophagitis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Eosinophilic Esophagitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Eosinophilic Esophagitis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Eosinophilic Esophagitis drugs and therapies
https://www.delveinsight.com/sample-request/eosinophilic-esophagitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Eosinophilic Esophagitis Pipeline Market Drivers
• Increasing awareness programs for Eosinophil-associated disorders
• Introduction of high-priced biologics

Eosinophilic Esophagitis Pipeline Market Barriers
• Increasing awareness programs for Eosinophil-associated disorders
• Introduction of high-priced biologics.

Scope of Eosinophilic Esophagitis Pipeline Drug Insight
• Coverage: Global
• Key Eosinophilic Esophagitis Companies: Serpin Pharma, Landos Biopharma, Aqilion, Calypso Biotech, Pfizer, EsoCap, Revolo Biotherapeutics, Ellodi Pharmaceuticals, AstraZeneca, and others
• Key Eosinophilic Esophagitis Therapies: SP 16, Omilancor, AQ280, CALY-002, Etrasimod, Mometasone, IRL201104, APT-1011, Benralizumab, and others
• Eosinophilic Esophagitis Therapeutic Assessment: Eosinophilic Esophagitis current marketed and Eosinophilic Esophagitis emerging therapies
• Eosinophilic Esophagitis Market Dynamics: Eosinophilic Esophagitis market drivers and Eosinophilic Esophagitis market barriers

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.